Alkermes plc. General and Administrative Expense
Alkermes plc. (ALKS) reported General and Administrative Expense of $63.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-07-28
- Alkermes plc. general and administrative expense for the quarter ending 2026-06-30 was $63.26M, a 27.35% increase year-over-year.
- Alkermes plc. general and administrative expense for the quarter ending 2026-03-31 was $109.03M, a 123.56% increase year-over-year.
- Alkermes plc. general and administrative expense for the quarter ending 2025-12-31 was $66.92M, a 39.12% increase year-over-year.
- Alkermes plc. general and administrative expense for the quarter ending 2025-09-30 was $56.14M, a 16.14% increase year-over-year.
- Alkermes plc. general and administrative expense for fiscal 2025 was $221.51M, a 11.30% increase from fiscal 2024.
- Alkermes plc. general and administrative expense for fiscal 2024 was $199.02M, a 0.29% decline from fiscal 2023.
- Alkermes plc. general and administrative expense for fiscal 2023 was $199.60M, a 0.53% increase from fiscal 2022.
- Alkermes plc. general and administrative expense for fiscal 2022 was $198.54M.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.26M 10-Q · filed 2026-07-28 | $172.94M 10-Q · filed 2026-07-28 | $239.22M derived: sum of 3 quarters · filed 2026-07-28 | $295.36M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $109.03M 10-Q · filed 2026-05-05 | $175.96M derived: sum of 2 quarters · filed 2026-05-05 | $232.10M derived: sum of 3 quarters · filed 2026-05-05 | $281.77M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $66.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $123.07M derived: sum of 2 quarters · filed 2026-02-25 | $172.74M derived: sum of 3 quarters · filed 2026-07-28 | $221.51M 10-K · filed 2026-02-25 |
| 2025-09-30 | $56.14M 10-Q · filed 2025-10-28 | $105.82M derived: sum of 2 quarters · filed 2026-07-28 | $154.59M 10-Q · filed 2025-10-28 | $202.69M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $49.67M 10-Q · filed 2026-07-28 | $98.44M 10-Q · filed 2026-07-28 | $146.55M derived: sum of 3 quarters · filed 2026-07-28 | $194.89M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $48.77M 10-Q · filed 2026-05-05 | $96.88M derived: sum of 2 quarters · filed 2026-05-05 | $145.22M derived: sum of 3 quarters · filed 2026-05-05 | $193.66M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $48.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $96.45M derived: sum of 2 quarters · filed 2026-02-25 | $144.89M derived: sum of 3 quarters · filed 2026-02-25 | $199.02M 10-K · filed 2026-02-25 |
| 2024-09-30 | $48.34M 10-Q · filed 2025-10-28 | $96.78M derived: sum of 2 quarters · filed 2025-10-28 | $150.92M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $48.45M 10-Q · filed 2025-07-29 | $102.58M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $54.13M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $199.60M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $198.54M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |